Astrazeneca Plc ADR (AZN)
$76.80
0.00 (0.00%)
AZN Stock Quote Delayed 30 Minutes
Big Pharma Might Already Have Sights on Abbott Spinoff
Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
663
Day's Range
-
52-Week Range
$60.47 - $80.86
Dividend & Yield
$0.93 (1.21%)
AZN Stock Predictions, Articles, and Astrazeneca Plc ADR News
Big Pharma Stocks Have Big Challenges Ahead
Tougher FDA approvals and expiring patents mean good times for Big Pharma could be fleeting, but a few stocks are worth striking at while the iron's hot.
AstraZeneca Plagued By Purple Pill Problems
The company faces eroding sales of its blockbuster drugs.
